UK Startup Sends Drug-Making into Space
· news
The Cosmic Cure-All?
The latest frontier in pharmaceutical innovation is not just about pushing medical science to its limits, it’s also a business gamble of massive proportions. Last week, UK startup BioOrbit launched its Box-E unit into space aboard a SpaceX rocket, carrying revolutionary technology for producing ultra-pure protein crystals. The goal is to create self-injected cancer drugs that can be administered at home or work, rather than in hospitals.
According to Dr Katie King, CEO of BioOrbit, gravity negatively impacts crystallisation, which becomes critical for protein drugs. “Through going to space, you see a much better, more superior crystallisation process than what you can achieve here on Earth,” she explains. This technology has significant implications for the development of self-injected cancer drugs and could potentially open up new avenues for other treatments.
Assuming the orbital tests are successful, multiple Box-E units could be stacked together to ramp up pharmaceutical manufacturing in space. BioOrbit aims to process thousands of litres of fluid per box every year – enough to produce several blockbuster drugs with just a handful of boxes in constant use. The financial potential is eye-watering: King estimates that switching to self-injection at home could save the NHS and other health systems “millions, potentially billions” of pounds.
However, this business model depends on investors willing to take a gamble – and one that may not pay off for years to come. BioOrbit has already raised £9.8m from investors, led by LocalGlobe and Breega, but it will need significantly more funding to bring its technology to market. The competition is fierce: Elon Musk’s SpaceX is eyeing up in-space manufacturing of pharmaceuticals as a key revenue stream – and estimates that this market could be worth $22.7tn in enterprise applications.
BioOrbit wants to be part of this lucrative market, not just for cancer drugs but also for other treatments, including the 70% of big-selling drugs currently administered intravenously at hospitals or doctor’s offices. The crystallisation technology can be used for a wide range of pharmaceuticals, making it an attractive investment opportunity.
The idea of manufacturing pharmaceuticals in space is not new, but BioOrbit’s approach is innovative. By using microgravity to facilitate crystallisation, they’re able to produce protein crystals that are far more pure and stable than those produced on Earth. This has significant implications for the development of self-injected cancer drugs – and could potentially open up new avenues for other treatments.
BioOrbit’s partnership with pharmaceutical companies will be crucial in bringing its technology to market, but it’s clear that this is a high-risk gamble. The financial potential may be significant, but the timeline for returns on investment could stretch out over several years – or even decades.
As the space industry continues to grow and evolve, we’re seeing more and more examples of companies pushing the boundaries of what’s possible. SpaceX’s plans for in-space manufacturing are just one example – and BioOrbit’s gamble is another. Whether or not this pays off, it’s clear that the future of healthcare will be shaped by technological innovation and entrepreneurial spirit.
The stakes are high, but the potential rewards could be astronomical. Assuming the orbital tests are successful, what’s next for BioOrbit? Will they be able to scale up production and bring their technology to market – or will this project end up as just another footnote in the history of biotech innovation?
Reader Views
- CSCorrespondent S. Tan · field correspondent
"This space-based approach to pharmaceutical manufacturing is undeniably groundbreaking, but we should be cautious about overhyping its potential impact on healthcare costs. The article highlights Dr King's estimate of millions or even billions saved by NHS and other health systems, but what's less clear is how these savings will be distributed among various stakeholders – manufacturers, investors, patients, and governments. Will this innovation merely shift profit margins upwards or actually reduce healthcare expenses for those who need it most?"
- RJReporter J. Avery · staff reporter
While BioOrbit's Box-E technology has the potential to revolutionize pharmaceutical manufacturing, let's not get ahead of ourselves - we're still in the realm of theory here. The real challenge lies in scalability and regulation: how do you ensure quality control when producing drugs on a massive scale in space? And what about liability concerns if something goes wrong? Those are questions that investors and regulators will need to address before this concept becomes a reality, rather than just a promising idea with significant financial backing.
- ADAnalyst D. Park · policy analyst
While BioOrbit's ambitions are undeniably exciting, it's crucial to acknowledge that this innovation doesn't necessarily guarantee cost savings for health systems. Even if protein crystallisation is improved in space, the infrastructure and logistical costs of transporting drugs back to Earth could offset potential savings. Moreover, switching to self-injection at home will require significant investments in education, training, and patient support – factors that are often overlooked in discussions about the financial benefits of emerging technologies.